Exploring Cypriot Pharmacists' Perceptions about their Role in Cardiovascular Disease Prevention: A Descriptive Qualitative Study.
Cardiovascular disease prevention
Cypriot pharmacists
health promotion
pharmacy-led preventive services
Journal
Journal of research in pharmacy practice
ISSN: 2319-9644
Titre abrégé: J Res Pharm Pract
Pays: India
ID NLM: 101614023
Informations de publication
Date de publication:
Historique:
received:
20
08
2020
accepted:
30
11
2020
entrez:
23
7
2021
pubmed:
24
7
2021
medline:
24
7
2021
Statut:
epublish
Résumé
The age-standardized prevalence of cardiovascular diseases (CVDs) among the Cypriot population in 2017 was estimated to be 5552 per 100,000. Therefore, the CVD prevention in Cyprus is of paramount importance. Pharmacists are one of the most accessible health-care professionals (HCPs) and the first port of call for the public. In Cyprus, there are 55.59 pharmacies per 100,000 inhabitants. Therefore, the role of Cypriot pharmacists (CPs) in primary CVD prevention is essential. This study aimed to explore both the existing and potential future roles of CPs in CVD prevention. A descriptive qualitative study employing structured interviews (SIs) was conducted. Initially, the CPs were identified through a list provided by the Cypriot Pharmaceutical Services. The researcher(s) then contacted CPs by telephone. Face-to-face interviews were scheduled based on the CP's availability. In total, 21 SIs were transcribed verbatim, coded, and analyzed thematically. SIs continued until data saturation was achieved. The findings are reported under the themes of pharmacists' knowledge and role, resources/tools available and training, communication and relations, and barriers. CPs expressed the need for training, and they are ready to have a more proactive role within the primary health care. The main barrier identified was the lack of responsiveness of the public and the lack of CP's time. CPs have the potential to actively participate in CVD prevention in Cyprus. CPs want to start offering primary CVD health services, with the smoking cessation being the first intervention.
Identifiants
pubmed: 34295849
doi: 10.4103/jrpp.JRPP_20_102
pii: JRPP-10-23
pmc: PMC8259602
doi:
Types de publication
Journal Article
Langues
eng
Pagination
23-29Informations de copyright
Copyright: © 2021 Journal of Research in Pharmacy Practice.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Pharmacy (Basel). 2018 Sep 17;6(3):
pubmed: 30227594
Int J Pharm Pract. 2018 Apr;26(2):120-128
pubmed: 28543969
Pharmacy (Basel). 2019 Jul 03;7(3):
pubmed: 31277208
J Am Coll Cardiol. 2012 Dec 25;60(25 Suppl):S1-49
pubmed: 23257320
Open Heart. 2018 Jan 3;5(1):e000687
pubmed: 29344376
Int J Qual Health Care. 2007 Dec;19(6):349-57
pubmed: 17872937
Int J Clin Pharm. 2014 Aug;36(4):800-6
pubmed: 25027254
Eval Health Prof. 2010 Mar;33(1):81-95
pubmed: 20042417
Pharmacy (Basel). 2015 Oct 13;3(4):154-168
pubmed: 28975910
J Res Pharm Pract. 2019 Oct 16;8(3):112-122
pubmed: 31728341
BMC Health Serv Res. 2017 Mar 21;17(1):224
pubmed: 28327136
Trials. 2015 Feb 26;16:65
pubmed: 25885807
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
BMC Public Health. 2017 Feb 20;17(1):215
pubmed: 28219367
Res Social Adm Pharm. 2017 May - Jun;13(3):440-455.e11
pubmed: 27459951
Biosci Trends. 2018 Jan 9;11(6):632-639
pubmed: 29249774